agoraphobia, generalised anxiety disorder) Psychotic disorder (schizophrenia and schizoaffective disorder), Mood disorder (major depressive disorder and bipolar disorder (currently depressive episode)) Anxiety disorder (panic disorder, social phobia, specific phobia
Conditions
Brief summary
Patient recovery at 24 weeks, as assessed using the patient recovery assessment scale (RAS, RAS-DS))
Detailed description
Well-being and quality of life (EuroQol 5 Dimensions-5 levels questionnaire; EQ-5D-5L). Psychosocial functioning (Functioning Assessment Short Test (FAST)). Clinical symptomatology (SIGH-D; for patients with mood disorders), (SIGH-A; anxiety disorders), and the PANSS (for psychotic patients). Side effects (Frequency, Intensity and Burden of side effects ratings (FIBSER) and the Udvalg for Kliniske Undersogelse – Side Effects Rating Scale (UKU-SERS)). Obtained over a 24-week period
Interventions
DRUGARIPIPRAZOLE
DRUGESCITALOPRAM
DRUGRISPERIDONE
DRUGSERTRALINE
Sponsors
Parnassia Groep B.V.
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient recovery at 24 weeks, as assessed using the patient recovery assessment scale (RAS, RAS-DS)) | — |
Secondary
| Measure | Time frame |
|---|---|
| Well-being and quality of life (EuroQol 5 Dimensions-5 levels questionnaire; EQ-5D-5L). Psychosocial functioning (Functioning Assessment Short Test (FAST)). Clinical symptomatology (SIGH-D; for patients with mood disorders), (SIGH-A; anxiety disorders), and the PANSS (for psychotic patients). Side effects (Frequency, Intensity and Burden of side effects ratings (FIBSER) and the Udvalg for Kliniske Undersogelse – Side Effects Rating Scale (UKU-SERS)). Obtained over a 24-week period | — |
Countries
Germany, Spain
Outcome results
None listed